PPIDT00328
Drug Information
| Name | Sotatercept |
|---|---|
| Sequence | ILGRSETQECLFFNANWEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSNPVTPKPPTGGGTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPVPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB12118 |
| Type | biotech |
| Indication | Sotatercept is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events.[L50351] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Subcutaneous |
45 mg
|
| Injection, powder, for solution | Subcutaneous |
60 mg
|
| Injection, powder, lyophilized, for solution; injection, solution; kit | Subcutaneous |
|
| Kit; powder, for solution | Subcutaneous |
45 mg / vial
|
| Kit; powder, for solution | Subcutaneous |
60 mg / vial
|
| Powder, for solution | Subcutaneous |
45 mg / vial
|
| Powder, for solution | Subcutaneous |
60 mg / vial
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P27037 | ACVR2A | Activin receptor type-2A | Homo sapiens | binder | Link |
| target | P36896 | ACVR1B | Activin receptor type-1B | Homo sapiens | binder | Link |
| target | O14793 | MSTN | Growth/differentiation factor 8 | Homo sapiens | binder | Link |
| target | O95390 | GDF11 | Growth/differentiation factor 11 | Homo sapiens | binder | Link |